MA53338A - Dosages pour détecter la neurodégénérescence - Google Patents

Dosages pour détecter la neurodégénérescence

Info

Publication number
MA53338A
MA53338A MA053338A MA53338A MA53338A MA 53338 A MA53338 A MA 53338A MA 053338 A MA053338 A MA 053338A MA 53338 A MA53338 A MA 53338A MA 53338 A MA53338 A MA 53338A
Authority
MA
Morocco
Prior art keywords
assays
neurodegeneration
detecting
detecting neurodegeneration
Prior art date
Application number
MA053338A
Other languages
English (en)
Inventor
Hartmuth Christian Kolb
John Randall Slemmon
Gallen Triana-Baltzer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53338A publication Critical patent/MA53338A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053338A 2018-03-05 2019-03-04 Dosages pour détecter la neurodégénérescence MA53338A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862638524P 2018-03-05 2018-03-05

Publications (1)

Publication Number Publication Date
MA53338A true MA53338A (fr) 2022-01-05

Family

ID=67768541

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053338A MA53338A (fr) 2018-03-05 2019-03-04 Dosages pour détecter la neurodégénérescence

Country Status (16)

Country Link
US (3) US10591492B2 (fr)
EP (1) EP3762414A4 (fr)
JP (2) JP7399096B2 (fr)
KR (1) KR20200130354A (fr)
CN (1) CN112105640A (fr)
AU (1) AU2019232630A1 (fr)
BR (1) BR112020018193A2 (fr)
CA (1) CA3093198A1 (fr)
EA (1) EA202092087A1 (fr)
IL (1) IL277077A (fr)
JO (1) JOP20200216A1 (fr)
MA (1) MA53338A (fr)
MX (1) MX2020009278A (fr)
PH (1) PH12020551371A1 (fr)
SG (1) SG11202008574VA (fr)
WO (1) WO2019171258A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4040153A4 (fr) * 2019-09-30 2023-07-26 Nipro Corporation Procédé de détection d'une protéine tau au moyen d'un échantillon de sang en tant que spécimen
AU2021309020A1 (en) 2020-07-14 2023-03-09 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
EP4232155A1 (fr) 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Procédés de réduction de la protéine tau chez des sujets humains
BR112023014151A2 (pt) * 2021-02-19 2023-10-10 Eisai R&D Man Co Ltd Anticorpo tau anti-pt217
WO2023056410A1 (fr) * 2021-10-01 2023-04-06 Integrated Neurologics LLC Méthodes et dispositifs de détection de fuite de liquide céphalo-rachidien
WO2023092004A1 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à tau
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
JP7450995B1 (ja) 2023-04-13 2024-03-18 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
CA2178212C (fr) 1993-12-21 2011-06-14 Marc Vandermeeren Anticorps monoclonaux specifiques de phf-tau, hybridomes les secretant, reconnaissance des antigenes par ces anticorps et leurs applications
WO1996004309A1 (fr) 1994-07-29 1996-02-15 Innogenetics N.V. Anticorps monoclonaux specifiques d'un epitope d'une sous-classe ou forme particuliere de tau phosphorylee, hybridomes les secretant, reconnaissance par les antigenes de ces anticorps et leurs applications
DE60032905T2 (de) 1999-07-06 2007-10-18 Eli Lilly And Co., Indianapolis Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
EP4218794A3 (fr) * 2009-06-10 2023-09-13 New York University Ciblage immunologique de protéines tau pathologiques
WO2011026031A1 (fr) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Anticorps liant les oligomères de la protéine tau
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SI2794654T1 (sl) 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
WO2014011972A1 (fr) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Immunodosage de tau
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US10400034B2 (en) * 2014-06-26 2019-09-03 Janssen Vaccines & Prevention, B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2016270858B2 (en) * 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Also Published As

Publication number Publication date
MX2020009278A (es) 2021-01-08
KR20200130354A (ko) 2020-11-18
CA3093198A1 (fr) 2019-09-12
US20200182888A1 (en) 2020-06-11
JOP20200216A1 (ar) 2020-09-03
US20190271710A1 (en) 2019-09-05
US20200408781A1 (en) 2020-12-31
BR112020018193A2 (pt) 2021-02-02
EP3762414A4 (fr) 2022-01-05
PH12020551371A1 (en) 2021-08-23
JP2021517239A (ja) 2021-07-15
CN112105640A (zh) 2020-12-18
AU2019232630A1 (en) 2020-09-24
JP2024037794A (ja) 2024-03-19
JP7399096B2 (ja) 2023-12-15
US10591492B2 (en) 2020-03-17
EA202092087A1 (ru) 2020-11-17
EP3762414A1 (fr) 2021-01-13
SG11202008574VA (en) 2020-10-29
IL277077A (en) 2020-10-29
WO2019171258A1 (fr) 2019-09-12
US10976325B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MA53338A (fr) Dosages pour détecter la neurodégénérescence
HRP20190026T1 (hr) Testovi za određivanje prisutnosti ili količine protutijela protiv lijeka
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
DK3455257T3 (da) Anti-pd-l1-antistoffer
MA53434A (fr) Anticorps anti-tigit
MA46057A (fr) Anticorps anti-ctla4
MA45783A (fr) Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
FR3044432B1 (fr) Systeme d'actionnement pour aeronef.
MA52366A (fr) Anticorps anti-tl1a optimisés
FR3042807B1 (fr) Autolestage pour banche de coffrage
MA52191A (fr) Carrosserie ouvrante pour une sous-structure
MA52152A (fr) Anticorps
MA52545A (fr) Anticorps pour radionucléides chélatés
MA42706A (fr) Anticorps et dosages pour la détection de cd37
DK3328886T3 (da) Tungkæde antistoffer over for ang-2
FR3047059B1 (fr) Ensemble de raccord pour tube
MA53160A (fr) Récepteur pour vista
MA54500A (fr) Vitre pour un véhicule
DK3849976T3 (da) GABAA-receptorligand
MA47133A (fr) Dispositif de caisse à claire-voie pour boîtes
FR3046351B1 (fr) Chariot- portoir pour brancard.
FR3046350B1 (fr) Chariot- portoir pour un brancard.
FR3042395B1 (fr) Ensemble de construction pour structure d'ameublement.
FR3049751B1 (fr) Perfectionnement pour accordeon
JP1672956S (ja) 液体注出具